Advances in the understanding and classification of pulmonary hypertension

Histopathology

Volumn 54, Issue 1, 2009, Pages 104-116

  Stewart, Susan ^a   Rassl, Doris ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

Aetiology; Morphology; Pathogenesis; Pulmonary hypertension

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2;

ARTERITIS; ARTERY DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL FEATURE; DISEASE CLASSIFICATION; ENDARTERECTOMY; FAMILIAL PULMONARY ARTERIAL HYPERTENSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; MORPHOMETRICS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERIOPATHY; PULMONARY CAPILLARY HEMANGIOMATOSIS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REVIEW; VASCULAR DISEASE;

HUMANS; HYPERTENSION, PULMONARY; PREVALENCE; PULMONARY CIRCULATION;

EID: 58449122495     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03180.x     Document Type: Review

References (64)

1. Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2004 43 (12 Suppl S 405 407.
2. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension 1. Clinical and hemodynamic study. Am. J. Med. 1951 11 686 705.
3. Hatano S, Strasser T. Primary pulmonary hypertension: a report on a WHO meeting. Geneva : World Health Organization, 1973 7 45.
4. Rich SE. Primary pulmonary hypertension: executive summary from the World Symposium-primary pulmonary hypertension. Available at http://www.who.int/ncd/ pph.html.1998.
5. Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2004 43 (12 Suppl S 5S 12S.
6. Yi ES, Kim H, Ahn H et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am. J. Respir. Crit. Care Med. 2000 162 1577 1586.
7. Jamison BM, Michel RP. Different distribution of plexiform lesions in primary and secondary pulmonary hypertension. Hum. Pathol. 1995 26 987 993.
8. Chazova I, Loyd JE, Zhdanov VS et al. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am. J. Pathol. 1995 146 339 397.
9. Wagenvoort CA, Wagenvoort N. Pathology of pulmonary hypertension. New York, NY : John Wiley, 1977.
10. Pietra GG, Capron F, Stewart S et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J. Am. Coll. Cardiol. 2004 43 (12 Suppl S 25S 32S.
11. Pietra GG. The pathology of primary pulmonary hypertension. In Rubin LJ, Rich S eds. Primary pulmonary hypertension: lung biology in health and disease. Vol. 99. New York, NY : Marcel Dekker, 1997 19 61.
12. Asosingh K, Aldred MA, Vasanji A et al. Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am. J. Pathol. 2008 172 615 627.
13. Arciniegas E, Frid MG, Douglas IS et al. Perspectives on endothelial-mesenchymal transition: potential contribution to vascular remodelling in chronic pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 2007 293 L1 L8.
14. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993 103 685 692.
15. Lee SD, Shroyer KR, Markham NE et al. Monoclonal endothelial proliferation is present in primary but not secondary pulmonary hypertension. J. Clin. Invest. 1998 101 927 934.
16. Yeager ME, Halley GR, Golpon HA et al. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ. Res. 2001 88 e2 e11.
17. Cool CD, Stewart JS, Werahera P et al. Three-dimension reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am. J. Pathol. 1999 155 411 419.
18. Wagenvoort CA, Wagenvoort N. The pathology of pulmonary veno-occlusive disease. Virchows Arch. A Path. Anat. Histol. 1974 364 69 79.
19. Capron F. Lavage broncho-alveolaire et hemorragie alveolaire. Ann. Pathol. 2002 222 782 788.
20. Rabiller A, Humbert M, Sitbon O et al. Bronchoalveolar lavage as a diagnostic tool in pulmonary hypertension: occult alveolar hemorrhage is a common feature of pulmonary veno-occlusive disease (abstr). Am. J. Respir. Crit. Care Med. 2003 167 A276.
21. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am. J. Crit. Care Med. 2000 162 1964 1973.
22. Palmer SM, Robinson LJ, Wang A et al. Massive pulmonary oedema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998 113 237 240.
23. Havlik DM, Massie LW, Williams WL, Crookes LA. Pulmonary capillary hemangiomatosis-like foci. An autopsy study of 8 cases. Am. Clin. Pathol. 2000 113 655 662.
24. Tron V, Magee F, Wright JL, Colby T, Churg A. Pulmonary capillary hemangiomatosis. Hum. Pathol. 1986 93 657 659.
25. Almagro P, Julia J, Sanjaume M et al. Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: report of 2 new cases and review of 35 cases from the literature. Medicine 2002 81 417 424.
26. Jing X, Yokoi T, Nakamura Y et al. Pulmonary capillary hemangiomatosis. A unique feature of congestive vasculopathy associated with hypertrophic cardiomyopathy. Arch. Pathol. Lab. Med. 1998 122 94 96.
27. Lanteuejoul S, Sheppard MN, Corrin B, Burke MM, Nicholson AG. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Am. J. Surg. Pathol. 2006 30 850 857.
28. Eltorky MA, Headley AS, Winer-Muram H et al. Pulmonary capillary hemangiomatosis: a clinicopathologic review. Ann. Thorac. Surg. 1994 57 772 776.
29. Faber CN, Yousem SA, Dauber JH et al. Pulmonary capillary hemangiomatosis. A report of three cases and a review of the literature. Am. Rev. Dis. 1989 140 808 813.
30. Wagenvoort CA, Wagenvoort N, Takahashi T. Pulmonary veno-occlusive disease: involvement of pulmonary arteries and review of the literature. Hum. Pathol. 1985 16 1033 1041.
31. Auger WR, Kim NH, Kerr KM et al. Chonic thromboembolic pulmonary hypertension. Clin. Chest Med. 2007 28 255 269.
32. Sztrymf B, Yaici A, Girerd B, Humbert M. Genes and pulmonary hypertension. Respiration 2007 74 123 132.
33. Condliffe R, Kiely DG, Gibbs JS et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2008 177 1122 1127.
34. Chong S, Kim TS, Kim BT et al. Pulmonary artery sarcoma mimicking pulmonary thromboembolism: integrated FDG PET/CT. AJR Am. J. Roentenol. 2007 188 1691 1693.
35. Moser KM, Yung GL, Marsh JJ et al. Pulmonary vascular remodelling distal to pulmonary artery ligation is accompanied by upregulation of endothelin receptors and nitric oxide synthase. Exp. Lung Res. 2000 26 287 301.
36. Sacks RS, Remillard CV, Agange N et al. Molecular biology of chronic thromboembolic pulmonary hypertension. Semin. Thorac. Cardiovasc. Surg. 2006 18 265 276.
37. Dartevelle P, Fadel E, Mussot S et al. Chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 2004 23 637 648.
38. Galié N, Kim NH. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc. Am. Thorac. Soc. 2006 3 571 576.
39. Aldred MA, Machado RD, James V et al. Characterization of the BMPR2 5'-untranslated region and novel mutation in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2007 176 819 824.
40. Thompson JR, Machado RD, Pauciulo MW et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II a receptor member of the TGF-beta family. J. Med. Genet. 2000 37 741 745.
41. Atkinson C, Stewart S, Upton PD et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002 105 1672 1678.
42. Zhang S, Fantozzi I, Tigno DD et al. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2003 285 L740 L754.
43. Upton PD, Long L, Trembath RC et al. Functional characterization of bone morphogenetic protein binding sites and Smad 1/5 activation in human vascular cells. Mol. Pharmcol. 2008 73 539 552.
44. Morrell NW. Pulmonary hypertension due to BMPR2 mutation, a new paradigm for tissue remodelling? Proc. Am. Thorac. Soc. 2006 3 680 686.
45. Reynolds AM, Xia W, Holmes MD et al. Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 2007 292 L1182 L1192.
46. Southwood M, Jeffrey TK, Yang X et al. Regulation of bone morphogenetic protein signalling in human pulmonary vascular development. J. Pathol. 2008 214 85 95.
47. McDonald PP, Fadok VA, Bratton D et al. Transcriptional and translocational regulation of inflammatory mediator production by endogenous TGF-β in macrophages that have ingested apoptotic cells. J. Immunol. 1999 163 6164 6172.
48. Runo JR, Vnencak-Jones CL, Prince M et al. Pulmonary veno-occlusive disease caused by an inherited mutation in BMPR2. Am. J. Respir. Crit. Care Med. 2003 167 889 894.
49. Machado RD, Aldred MA, Harrison J et al. Mutations of the TGF-β type II receptor BMPR2 in pulmonary arterial hypertension. Hum. Mutat. 2006 27 121 132.
50. Yuan J-X, Rubin LJ. Pathogenesis of pulmonary arterial hypertension, the need for multiple hits. Circulation 2005 111 534 538.
51. MacLean MR. Pulmonary hypertension and the serotonin hypothesis: where are we now? Int. J. Clin. Pract. 2007 61 (Suppl 156 27 31.
52. Eddahibi S, Humbert M, Fadel E et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 2001 108 1109 1111.
53. Chan SY, Loscaizo J. Pathogenic mechanisms of pulmonary arterial hypertension. J. Mol. Cell. Cardiol. 2008 44 14 30.
54. Dorfmuller P, Humbert M, Perros F et al. Fibrous remodelling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum. Pathol. 2007 38 893 902.
55. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur. Repir. J. 2008 31 1357 1367.
56. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung disease. Mayo Clin. Proc. 2007 82 342 350.
57. Carreira E. Pulmonary hypertension in autoimmune rheumatic diseases. Autoimmun. Rev. 2004 3 313 320.
58. Mannino D. Is systemic inflammation responsible for pulmonary hypertension in COPD. Chest 2006 130 318 325.
59. Pak O, Aldashev A, Welsh D, Peacock A. The effects of hypoxia on the cells of the pulmonary vasculature. Eur. Respir. J. 2007 30 364 372.
60. Hagen M, Fagan L, Steudel W et al. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am. J. Physiol. Lung Cell Mol. Physiol. 2007 292 L1473 L1479.
61. Rosenweig EB, Morse JH, Knowles JA et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J. Heart Lung Transplant. 2008 27 668 674.
62. Elliot C, Glissmeyer EW, Havlena GT et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 2006 113 2509 2515.
63. Sztrymf B, Coulet F, Girerd B et al. Clinical carriers of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am. J. Resp. Crit. Care Med. 2008 177 1377 1383.
64. Deutsch GH, Young LR, Deterding RR et al. Diffuse lung disease in young children. Am. J. Resp. Crit. Care Med. 2008 176 1120 1128.